Notices. Notice of Commission determinations to conduct full five-year reviews concerning the countervailing duty order on stainless steel bar from Italy and the antidumping duty orders on stainless steel bar from France, Germany, Italy, Korea, and the United Kingdom
7,073 words·~32 min read·
/register/2007/05/18/07-2503A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4310-WV-M INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701-TA-413 and 731-TA-913-916 and 918 (Review)] Stainless Steel Bar From France, Germany, Italy, Korea, and The United Kingdom AGENCY: United States International Trade Commission. ACTION: Notice of Commission determinations to conduct full five-year reviews concerning the countervailing duty order on stainless steel bar from Italy and the antidumping duty orders on stainless steel bar from France, Germany, Italy, Korea, and the United Kingdom.
SUMMARY: The Commission hereby gives notice that it will proceed with full reviews pursuant to section 751(c)(5) of the Tariff Act of 1930 (19 U.S.C. 1675(c)(5)) to determine whether revocation of the countervailing duty order on stainless steel bar from Italy and the antidumping duty orders on stainless steel bar from France, Germany, Italy, Korea, and the United Kingdom would be likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time.
A schedule for the reviews will be established and announced at a later date. For further information concerning the conduct of these reviews and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207). Effective Date: May 7, 2007. FOR FURTHER INFORMATION CONTACT: Mary Messer (202-205-3193), Office of Investigations, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436.
Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000. General information concerning the Commission may also be obtained by accessing its Internet server ( *http://www.usitc.gov* ). The public record for these reviews may be viewed on the Commission's electronic docket
(EDIS)at *http://edis.usitc.gov.* SUPPLEMENTARY INFORMATION: On May 7, 2007, the Commission determined that it should proceed to full reviews in the subject five-year reviews pursuant to section 751(c)(5) of the Act. The Commission found that the domestic interested party group response to its notice of institution (72 FR 4293, January 30, 2007) was adequate and that the respondent interested party group responses with respect to France, Germany, and the United Kingdom were adequate and decided to conduct full reviews with respect to the antidumping duty orders concerning stainless steel bar from France, Germany, and the United Kingdom. The Commission found that the respondent interested party group responses with respect to Italy and Korea were inadequate. 1 However, the Commission determined to conduct full reviews concerning the countervailing duty order on stainless steel bar from Italy and the antidumping duty orders on stainless steel bar from Italy and Korea to promote administrative efficiency in light of its decision to conduct full reviews with respect to the orders concerning stainless steel bar from France, Germany, and the United Kingdom. A record of the Commissioners' votes, the Commission's statement on adequacy, and any individual Commissioner's statements will be available from the Office of the Secretary and at the Commission's Web site. 1 Commissioners Lane and Williamson dissented with respect to the adequacy of the Italian respondent interested party group response, finding that the Italian respondent interested party group response was adequate. Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission's rules. By order of the Commission. Issued: May 14, 2007. William R. Bishop, Acting Secretary to the Commission. [FR Doc. E7-9560 Filed 5-17-07; 8:45 am] BILLING CODE 7020-02-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated January 23, 2007, and published in the **Federal Register** on January 30, 2007, (72 FR 4296), American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule 1-[1-(2-Thienyl) cyclohexyl] piperidine; TCP
(7470)I Normorphine
(9313)I Dextropropoxyphene, bulk (non-dosage form)
(9273)II The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of American Radiolabeled Chemical, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated American Radiolabeled Chemical, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9611 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated February 14, 2007 and published in the **Federal Register** on February 22, 2007, (72 FR 8017), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II. The company plans to import Phenylacetone for use as a precursor in the manufacture of amphetamines only. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Cambrex Charles City, Inc. to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9609 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated October 25, 2006, and published in the **Federal Register** on November 1, 2006, (71 FR 64298), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Sufentanil (9740), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex Charles City, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9625 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated January 16, 2007, and published in the **Federal Register** on January 23, 2007, (72 FR 2907), Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Tetrahydrocannabinols
(7370)I Dihydromorphine
(9145)I Dihydrocodeine
(9120)II Oxycodone
(9143)II Hydromorphone
(9150)II Hydrocodone
(9193)II Sufentanil
(9740)II Fentanyl
(9801)II Remifentanil
(9739)II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9642 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated November 21, 2006, and published in the **Federal Register** on December 1, 2006, (71 FR 69589-69590), Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal and by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule 4-Methoxyamphetamine
(7411)I Dihydromorphine
(9145)I Difenoxin
(9168)I Amphetamine
(1100)II Methamphetamine
(1105)II Methylphenidate
(1724)II Pentobarbital
(2270)II Codeine
(9050)II Dihydrocodeine
(9120)II Oxycodone
(9143)II Hydromorphone
(9150)II Hydrocodone
(9193)II Meperidine
(9230)II Dextropropoxyphene, bulk (non-dosage forms)
(9273)II Morphine
(9300)II Thebaine
(9333)II Oxymorphone
(9652)II Noroxymorphone
(9668)II Alfentanil
(9737)II Sufentanil
(9740)II Fentanyl
(9801)II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. By letter dated February 15, 2007, Chattem Chemicals has withdrawn their request for N-Ethylamphetamine (1475), Secobarbital (2315), 2,5-Dimethoxyamphetamine (7396), Diphenoxylate (9170), Opium Extracts (9610), Opium Fluid Extract (9620), Opium Tincture (9630), Opium Powdered (9639), and Opium Granulated (9640). One comment has been received; this comment has been noted and considered by DEA. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Chattem Chemicals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chattem Chemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9644 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 28, 2006, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Dihydromorphine
(9145)I Amphetamine
(1100)II Methamphetamine
(1105)II Amobarbital
(2125)II Pentobarbital
(2270)II Secobarbital
(2315)II Cocaine
(9041)II Oxycodone
(9143)II Hydromorphone
(9150)II Diphenoxylate
(9170)II Meperidine
(9230)II Oxymorphone
(9652)II Sufentanil
(9740)II Fentanyl
(9801)II The company plans on manufacturing the listed controlled substance in bulk for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to bulk manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative(ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative(ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 17, 2007. Dated: May 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9608 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated February 5, 2007 and published in the **Federal Register** on February 12, 2007, (72 FR 6578-6579), Fisher Clinical Services Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as an importer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for analytical research and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Fisher Clinical Services Inc. to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Fisher Clinical Services Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9610 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated November 21, 2006 and published in the **Federal Register** on December 1, 2006, (71 FR 69590), Formulation Technologies LLC, 11400 Burnet Road, Suite 4010, Austin, Texas 78758, made application to the Drug Enforcement Administration
(DEA)to be registered as an importer of Fentanyl (9801), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for clinical trials, research, analytical purposes and distribution to its customers. One objection was received; however, it has subsequently been withdrawn. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Formulation Technologies LLC to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Formulation Technologies LLC to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: May 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9606 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the **Federal Register** on December 22, 2006, (71 FR 77065-77066), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of 14-Hydroxymorphinone (9654), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substances in bulk as an intermediate for use in the production of another controlled substance. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9617 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated November 2, 2006, and published in the **Federal Register** on November 8, 2006, (71 FR 65544), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Nabilone
(7379)II Noroxymorphone
(9668)II The company plans to manufacture the listed controlled substances in bulk for sales to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9629 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the **Federal Register** on December 22, 2006, (71 FR 77065), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans on producing this item for sale to its customers, who are final dosage manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 9, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9634 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the **Federal Register** on December 22, 2006, (71 FR 77065-77066), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of 14-Hydroxymorphinone (9654), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substances in bulk as an intermediate for use in the production of another controlled substance. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 9, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9639 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated January 23, 2007, and published in the **Federal Register** on January 30, 2007, (72 FR 4298), Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Codeine-N-oxide
(9053)I Difenoxin
(9168)I Dihydromorphine
(9145)I Morphine-N-oxide
(9307)I Norlevorphanol
(9634)I Normorphine
(9313)I Tetrahydrocannabinols
(7370)I Nabilone
(7379)II Alfentanil(9737) II Amphetamine
(1100)II Ecgonine
(9180)II Codeine
(9050)II Dextropropoxyphene, bulk(9273) II Dihydrocodeine
(9120)II Diphenoxylate
(9170)II Diprenorphine
(9058)II Etorphine HCL
(9059)II Fentanyl(9801) II Hydrocodone
(9193)II Hydromorphone
(9150)II Levo-alphacetylmethadol
(9648)II Levorphanol(9220) II Meperidine
(9230)II Methadone
(9250)II Methadone intermediate
(9254)II Methamphetamine
(1105)II Methylphenidate
(1724)II Metopon
(9260)II Morphine
(9300)II Opium extracts
(9610)II Opium fluid extract
(9620)II Opium tincture
(9630)II Opium, granulated
(9640)II Opium, powdered
(9639)II Oxycodone
(9143)II Oxymorphone
(9652)II Noroxymorphone
(9668)II Phenazocine
(9715)II Alfentanil(9737) II Remifentanil
(9739)II Sufentanil(9740) II Thebaine
(9333)II The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Mallinckrodt Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Mallinckrodt Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9619 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated February 5, 2007 and published in the **Federal Register** on February 12, 2007, (72 FR 6579), Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Phenylacetone
(8501)II Coca Leaves
(9040)II Opium, raw
(9600)II Poppy Straw
(9650)II Poppy Straw Concentrate
(9670)II The company plans to import the listed controlled substances for the manufacture of controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Mallinckrodt Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Mallinckrodt Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9635 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated August 15, 2006, and published in the **Federal Register** on August 22, 2006, (71 FR 48947), Noramco Inc., Division of Ortho-McNeil, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal, and by separate correspondence dated June 2, 2006, and July 25, 2006, to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Codeine-N-Oxide
(9053)I Morphine-N-Oxide
(9307)I Codeine
(9050)II Dihydrocodeine
(9120)II Oxycodone
(9143)II Dihydromorphine
(9145)II Hydrocodone
(9193)II Thebaine
(9333)II Morphine
(9300)II Oxymorphone
(9652)II The company plans to bulk manufacture the above listed controlled substances for sale and distribution to manufacturers for product development and formulation. By letter dated January 4, 2007, Noramco has withdrawn their request for Amphetamine
(1100)and Methylphenidate (1724). No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 8, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9631 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 26, 2006, and published in the **Federal Register** on August 2, 2006, (71 FR 43814), Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Methylphenidate (1724), a basic class of controlled substance listed in schedule II. The company plans to bulk manufacture methylphenidate for a customer to use in the production of a controlled substance product. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9651 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the **Federal Register** on December 22, 2006, (71 FR 77066), Organichem Corporation, 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Marihuana
(7360)I Tetrahydrocannabinols
(7370)I Amphetamine
(1100)II Methylphenidate
(1724)II Pentobarbital
(2270)II Hydrocodone
(9193)II Meperidine(9230) II Dextropropoxyphene
(9273)II Fentanyl
(9801)II The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Organichem Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Organichem Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9612 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated January 16, 2007, and published in the **Federal Register** on January 23, 2007, (72 FR 2907), Organix Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in schedule I. The company plans on manufacturing this controlled substance for sale to its customers. These customers will sell the drug in small quantities for research purposes or as drug standards for forensic laboratories. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Organix Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Organix Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9630 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application This is notice that on March 7, 2007, Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration
(DEA)for registration as an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Coca Leaves
(9040)II Raw Opium
(9600)II Poppy Straw
(9650)II Concentrate of Poppy Straw
(9670)II The company plans to import the listed controlled substances to manufacture bulk controlled substance intermediates for sale to its customers. As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d),
(e)and
(f)are satisfied. Dated: May 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9645 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated November 28, 2006, and published in the **Federal Register** on December 7, 2006, (71 FR 70988), Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Oxymorphone (9652), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for conversion and sale to dosage form manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Rhodes Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Rhodes Technologies to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9614 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated October 31, 2006, and published in the **Federal Register** on November 7, 2006, (71 FR 65135), Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by letter to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Dihydromorphine
(9145)I Oxymorphone
(9652)II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siegfried (USA), Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Siegfried (USA), Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9615 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 26, 2006, and published in the **Federal Register** on August 2, 2006, (71 FR 43814-43815), Siegfried
(USA)Inc., 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as a bulk manufacturer of Hydromorphone (9150), a basic class of controlled substance listed in schedule II. The company plans to manufacture in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siegfried (USA), Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Siegfried (USA), Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9628 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated February 16, 2007, and published in the **Federal Register** on February 27, 2007 (72 FR 8793), Sigma Aldrich Manufacturing LLC., Subsidiary of Sigma-Aldrich Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made application by renewal to the Drug Enforcement Administration
(DEA)to be registered as an importer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule Cathinone
(1235)I Methcathinone
(1237)I Aminorex
(1585)I Gamma Hydroxybutyric Acid
(2010)I Methaqualone
(2565)I Ibogaine
(7260)I Lysergic acid diethylamide
(7315)I Marihuana
(7360)I Tetrahydrocannabinols
(7370)I Mescaline
(7381)I 4-Bromo-2,5-dimethoxyamphetamine
(7391)I 4-Bromo-2,5-dimethoxyphenethylamine
(7392)I 4-Methyl-2,5-dimethoxyamphetamine
(7395)I 2,5-Dimethoxyamphetamine
(7396)I 3,4-Methylenedioxyamphetamine
(7400)I N-Hydroxy-3,4-methylenedioxyamphetamine
(7402)I 3,4-Methylenedioxy-N-ethylamphetamine
(7404)I 3,4-Methylenedioxymethamphetamine
(7405)I 4-Methoxyamphetamine
(7411)I Bufotenine
(7433)I Diethyltryptamine
(7434)I Dimethyltryptamine
(7435)I Psilocybin
(7437)I Psilocyn
(7438)I N-Ethyl-1-phenylcyclohexylamine
(7455)I N-Benzylpiperazine
(7493)I Trifluoromethylphenyl Piperazine
(7494)I Heroin
(9200)I Normorphine
(9313)I Etonitazene
(9624)I Amphetamine
(1100)II Methamphetamine
(1105)II Methylphenidate
(1724)II Amobarbital
(2125)II Pentobarbital
(2270)II Secobarbital
(2315)II Glutethimide
(2550)II Nabilone
(7379)II Phencyclidine
(7471)II Cocaine
(9041)II Codeine
(9050)II Diprenorphine
(9058)II Oxycodone
(9143)II Hydromorphone
(9150)II Diphenoxylate
(9170)II Ecgonine
(9180)II Ethylmorphine
(9190)II Hydrocodone
(9193)II Levorphanol
(9220)II Meperidine
(9230)II Methadone
(9250)II Dextropropoxyphene, bulk (non-dosage forms)
(9273)II Morphine
(9300)II Thebaine
(9333)II Opium powdered
(9639)II Oxymorphone
(9652)II Fentanyl
(9801)II The company plans to import the listed controlled substances for sale to research facilities for drug testing and analysis. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Sigma Aldrich Manufacturing LLC. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Sigma Aldrich Manufacturing LLC. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-9604 Filed 5-17-07; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Foreign Claims Settlement Commission [F.C.S.C. Meeting Notice No. 4-07] Sunshine Act Meeting The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR Part 504) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of meetings for the transaction of Commission business and other matters specified, as follows: Date and Time: Thursday, May 31, 2007, at 1 p.m. Subject Matter: Issuance of Proposed Decisions and Amended Proposed Decisions in claims against Albania. Status: Open. All meetings are held at the Foreign claims Settlement Commission, 600 E Street, NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Administrative Officer, Foreign Claims Settlement Commission, 600 E Street, NW., Room 6002, Washington, DC 20579. Telephone:
(202)616-6988. Mauricio J. Tamargo, Chairman. [FR Doc. 07-2503 Filed 5-16-07; 11:26 am]
Connectionstraces to 7
Traces to 7 documents
U.S. Code
3 references not yet in our index
- 19 CFR 201
- 19 CFR 207
- 45 CFR 504
Citation graph
cites case law
Notices
Notice of Commission determinations to conduct full five-year reviews concerning the countervailing duty order on stainless steel bar from Italy and the antidumping duty orders on stainless steel bar from France, Germany, Italy, Korea, and the United Kingdom
Cite19 CFR 201
Cite19 CFR 207
Cite45 CFR 504
Cites 10Cited by 0 across 0 sources